Skip to main content
Webinar banner
AONM Webinar with Dr Shimasaki
Neuro-autoimmune conditions and how to test for them.

Dr. Shimasaki is CEO of Moleculera Labs, the only lab in the world to test for autoimmune activity against neuronal targets in the brain that is used by clinics/practitioners across the world to identify encephalitic-type activity called “PANS/PANDAS” in children, and autoimmune encephalopathy in adults. It is characterised by many symptoms that are often considered psychiatric and not given any further biomedical exploration. He will explain the use of the Cunningham Panel, how to interpret the results, and its application in therapy. This will be the first of three webinars on this topic.

CPD is pending.

Mar 26, 2019 6:30 PM in London

Webinar logo
* Required information


Dr. Craig Shimasaki
DR. CRAIG SHIMASAKI, PhD, MBA is President & CEO Moleculera Labs, Inc. He is a scientist with over 33 years of clinical diagnostic and therapeutic R&D experience, starting his career at Genentech. During his tenure he has been involved in the research, development and clinical testing of neuropsychiatric drugs and diagnostics, genetic testing for predisposition to non-familial breast cancer, a gp-120 HIV vaccine, and influenza and RSV diagnostics and therapeutics. He co-founded Moleculera Labs with Dr. Madeleine Cunningham, an autoimmune neurobiology clinical laboratory based upon her 20+ years of research on infection-triggered autoimmune disorders. His focus has been to translate basic research discoveries into acutely needed medical products for patients who need them. He has led five clinical diagnostic tests through FDA approval process and is a co-inventor on several medical and diagnostic patents.